TLDR Tech / Fintech
Kalshi launches prediction markets for drug trial results
Kalshi is expanding into biotechnology with contracts tied to clinical trial outcomes and FDA decisions, giving traders a way to isolate specific drug-development events from broader stock performance. Supporters say the markets could generate clearer probability signals for investors and patients, while critics warn they may encourage insider trading or influence trial behavior, prompting Kalshi to add employment checks and exclude pediatric or actively recruiting studies.
Read the full story